Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | HRH2 | P25021 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 8/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6857618 | 1.00 | SIGMAR1 (0.35) | SIGMAR1HRH2HRH1DRD2CACNA1H | |
| SCHEMBL2337700 | 1.00 | SIGMAR1 (0.35) | SIGMAR1HRH2HRH1DRD2CACNA1H | |
| SCHEMBL2361984 | 0.88 | CHRM2 (0.33) | SIGMAR1HRH2HRH1MEN1ALDH1A1 | |
| SCHEMBL2361985 | 0.88 | CHRM2 (0.33) | SIGMAR1HRH2HRH1MEN1ALDH1A1 | |
| SCHEMBL6857872 | 0.88 | CHRM2 (0.33) | SIGMAR1HRH2HRH1MEN1ALDH1A1 | |
| SCHEMBL19658018 | 0.81 | CYP1A2 (0.34) | SIGMAR1DRD2MEN1KMT2A | |
| SCHEMBL22986774 | 0.80 | CTSK (0.35) | KCNA3MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL15295730 | 0.80 | CTSK (0.35) | KCNA3MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL7040760 | 0.78 | CTSK (0.38) | MEN1KMT2A | |
| SCHEMBL7040763 | 0.78 | CTSK (0.38) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2534138-B1 | 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2017-01-25 | — | — | EP | disclosed |
| US-8809338-B2 | 1,2,3-triazole-based peptidomimetic integrin inhibitors for the diagnosis and therapy of tumors | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2014-08-19 | — | — | US | disclosed |
| US-20130040964-A1 | 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2013-02-14 | — | — | US | disclosed |
| EP-2534138-A1 | 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS | Universita' Degli Studi di Firenze (IT) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011098603-A1 | 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040964-A1 | 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS | ICAM1, ITGB3, VCAM1 | SIGMAR1 3017/4885HRH2 1236/4885HRH1 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.